Protecting-Group-Free Synthesis of GB1107: An Orally Active Galectin-3 Antagonist

Synthesis, Structure–Activity Relationships, and In Vivo Evaluation of Novel Tetrahydropyran-Based Thiodisaccharide Mimics as Galectin-3 Inhibitors

(2021) Li Xu et al.   JOURNAL OF MEDICINAL CHEMISTRY

The therapeutic potential of galectin-3 inhibition in fibrotic disease

(2020) R.J. Slack et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

An orally active galectin-3 antagonist inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade

(2019) Lynda Vuong et al.   CANCER RESEARCH

In Vivo Veritas: 18F-Radiolabeled Glycomimetics Allow Insights into the Pharmacological Fate of Galectin-3 Inhibitors

(2019) Klas Bratteby et al.   JOURNAL OF MEDICINAL CHEMISTRY

Galectin-3-Binding Glycomimetics that Strongly Reduce Bleomycin-Induced Lung Fibrosis and Modulate Intracellular Glycan Recognition

(2016) Tamara Delaine et al.   CHEMBIOCHEM

Enantioselective aldol reactions with masked fluoroacetates

(2016) Jakub Saadi et al.   Nature Chemistry

Investigating the Influence of (Deoxy)fluorination on the Lipophilicity of Non-UV-Active Fluorinated Alkanols and Carbohydrates by a New log P Determination Method

(2015) Bruno Linclau et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

The Roles of 3′ and 4′ Hydroxy Groups in α-Galactosylceramide Stimulation of Invariant Natural Killer T Cells

(2009) Chengfeng Xia et al.   ChemMedChem